Source: Eur Respir J 2015; 46: 243-249
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Collard Harold R., Bradford Williamson Z., Cottin Vincent, Flaherty Kevin R., King Talmadge E., Koch Gary G., Kolb Martin, Martinez Fernando J., Montgomery Bruce, Raghu Ganesh, Richeldi Luca, Rose Dan, Wells Athol U., Brown Kevin K.. A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. Eur Respir J 2015; 46: 243-249

Member's Comments

No comment yet.

Related content which might interest you: Idiopathic pulmonary fibrosis: current challenges and future perspectives Source: Eur Respir Rev 2013; 22: 103-105 Year: 2013 Idiopathic pulmonary fibrosis: present understanding and future options Source: Eur Respir Rev 2011; 20: 132-133 Year: 2011 Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential Source: Eur Respir Rev, 26 (145) 170071; 10.1183/16000617.0071-2017 Year: 2017 Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences Source: Eur Respir Rev 2015; 24: 420-427 Year: 2015 Generalisability of recent clinical trials in idiopathic pulmonary fibrosis to everyday clinical practice Source: International Congress 2015 – Treatment of IPF Year: 2015 Idiopathic pulmonary fibrosis: do scientists focus on publishing rather than on clinical relevance? Source: Eur Respir J, 55 (6) 2000811; 10.1183/13993003.00811-2020 Year: 2020 PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery Source: Eur Respir Rev 2013; 22: 148-152 Year: 2013 A registry of patients with idiopathic pulmonary fibrosis in Russia: 2-yr results and therapeutic modalities in real-life practice Source: International Congress 2019 – Interstitial lung disease registries Year: 2019 Diagnosis of idiopathic pulmonary fibrosis: from guidelines to clinical practice Source: Annual Congress 2009 - Clinical aspects of diffuse parenchymal lung disease Year: 2009 Idiopathic pulmonary fibrosis: treatment options in pursuit of evidence-based approaches Source: Eur Respir J 2006; 28: 463-465 Year: 2006 The concept of cystic fibrosis pulmonary exacerbation in clinical medicine and as a trial end-point Source: Annual Congress 2008 - Exacerbations of chronic respiratory disease – state of the art Year: 2008 Clinical trials in idiopathic pulmonary fibrosis: a framework for moving forward Source: Eur Respir J 2013; 42: 1446-1448 Year: 2013 The clinical efficacy of pulmonary hypertension-specific agents in idiopathic pulmonary fibrosis: A systematic review and meta-analysis Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years Source: Eur Respir J, 50 (4) 1701209; 10.1183/13993003.01209-2017 Year: 2017 Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis Source: Eur Respir Rev 2012; 21: 48-56 Year: 2012 Clinical trials in idiopathic pulmonary fibrosis: a word of caution concerning choice of outcome measures Source: Eur Respir J 2005; 26: 755-758 Year: 2005 What have we learned from basic science studies on idiopathic pulmonary fibrosis? Source: Eur Respir Rev, 28 (153) 190029; 10.1183/16000617.0029-2019 Year: 2019 The 2015 guidelines for idiopathic pulmonary fibrosis: an important chapter in the evolution of the management of patients with IPF Source: Eur Respir J 2015; 46: 883-886 Year: 2015 Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry Source: Eur Respir J 2015; 46: 186-196 Year: 2015